Given the impracticality of inhibiting dozens of deranged driver pathways in this patient’s disease with any targeted or conventional cytotoxic strategy, the identification of MMRD and PD-L1 over-expression provided a plausible hypothesis for controlling her metastatic cancer, even though neither biomarker was required for participating on this clinical trial. The gene discussed is CD274; the disease is metastatic malignant neoplasm.